TNDM 8-K
Tandem Diabetes Care Inc (TNDM)
8-K
2024-06-18
For: 2024-05-22
View Original
Added on
April 12, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2024
____________________________
(Exact name of registrant as specified in its charter)
____________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Zip Code) | ||||||||||||||
| (Address of principal executive offices) | ||||||||||||||
Registrant’s telephone number, including area code: (858 ) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________
Item 1.01 Entry into a Material Definitive Agreement.
On May 22, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Dexcom, Inc., a Delaware corporation (“Dexcom”) entered into an Amended and Restated Development Agreement to the Original Development Agreement, dated as of November 20, 2020, between the Company and Dexcom, under which the integration of the Company’s insulin pumps with Dexcom’s Continuous Glucose Monitoring (“CGM”) devices are addressed. The Amended and Restated Development Agreement incorporates the integration of the Company’s Sigi insulin pump with Dexcom’s G7 CGM device, extends the term for a period of five years, and amends certain definitions and terms and conditions related to devices and development generally.
On May 22, 2024, the Company and Dexcom also entered into an Amended and Restated Commercialization Agreement to the Original Commercialization Agreement, dated as of November 20, 2020, between the Company and Dexcom, under which the commercialization of the integrated solutions developed under the Amended and Restated Development Agreement are addressed. The Amended and Restated Commercialization Agreement incorporates the commercialization of the Company’s Sigi insulin pump with Dexcom’s G7 CGM device, extends the term for a period of five years, and amends certain definitions and terms and conditions related to devices and commercialization generally.
The Company intends to file both the Amended and Restated Development Agreement and the Amended and Restated Commercialization Agreement as exhibits to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2024.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Tandem Diabetes Care, Inc. | ||||||||
| By: | /s/ SHANNON M. HANSEN | |||||||
| Shannon M. Hansen | ||||||||
| Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary | ||||||||
Date: June 18, 2024
3